Pharmacotherapy of obesity: available medications and drugs under investigation

E Pilitsi, OM Farr, SA Polyzos, N Perakakis… - Metabolism, 2019 - Elsevier
Obesity is a chronic disease with a continuously rising prevalence that currently affects more
than half a billion people worldwide. Energy balance and appetite are highly regulated via …

Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update

K Albracht-Schulte, NS Kalupahana… - The Journal of nutritional …, 2018 - Elsevier
Strategies to reduce obesity have become public health priorities as the prevalence of
obesity has risen in the United States and around the world. While the anti-inflammatory and …

Long-term weight loss maintenance for obesity: a multidisciplinary approach

L Montesi, M El Ghoch, L Brodosi, S Calugi… - … syndrome and obesity …, 2016 - Taylor & Francis
The long-term weight management of obesity remains a very difficult task, associated with a
high risk of failure and weight regain. However, many people report that they have …

Probability of 5% or greater weight loss or BMI reduction to healthy weight among adults with overweight or obesity

L Kompaniyets, DS Freedman, B Belay… - JAMA Network …, 2023 - jamanetwork.com
Importance Information on the probability of weight loss among US adults with overweight or
obesity is limited. Objective To assess the probability of 5% or greater weight loss, 10% or …

Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier

M Van Hul, L Geurts, H Plovier… - American Journal …, 2018 - journals.physiology.org
Increasing evidence suggests that polyphenols have a significant potential in the prevention
and treatment of risk factors associated with metabolic syndrome. The objective of this study …

Safety and tolerability of new-generation anti-obesity medications: a narrative review

DK Patel, FC Stanford - Postgraduate medicine, 2018 - Taylor & Francis
The prevalence of obesity and associated comorbidities is rising. Despite their weight-loss
efficacy, new generation anti-obesity medications are only prescribed to a minority of adults …

PCSK1 mutations and human endocrinopathies: from obesity to gastrointestinal disorders

P Stijnen, B Ramos-Molina, S O'Rahilly… - Endocrine …, 2016 - academic.oup.com
Abstract Prohormone convertase 1/3, encoded by the PCSK1 gene, is a serine
endoprotease that is involved in the processing of a variety of proneuropeptides and …

[HTML][HTML] Current status of intragastric balloon for obesity treatment

SH Kim, HJ Chun, HS Choi, ES Kim… - World journal of …, 2016 - ncbi.nlm.nih.gov
Endoscopic bariatric therapy may be a useful alternative to pharmacological treatment for
obesity, and it provides greater efficacy with lower risks than do conventional surgical …

The pharmacological management of metabolic syndrome

J Rask Larsen, L Dima, CU Correll… - Expert review of clinical …, 2018 - Taylor & Francis
Introduction: The metabolic syndrome includes a constellation of several well-established
risk factors, which need to be aggressively treated in order to prevent overt type 2 diabetes …

Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients

H Mathew, OM Farr… - Metabolism: clinical and …, 2015 - pmc.ncbi.nlm.nih.gov
Obesity is most commonly defined as a BMI of over 30kg/m2. Typical classification is into
categories of Class I (BMI> 30 kg/m2), Class II (BMI equal to or over 35 kg/m2) and Class III …